First-in-class BRCA-positive Ovarian Cancer Medicine Lynparza® (olaparib) Receives Positive pan-Canadian Oncology Drug Review (pCODR) Recommendation for Provincial Reimbursement
This marks an important first step towards providing Canadian women with access to this treatment MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ - AstraZeneca Canada is pleased to announce that the pan-Canadian Oncology Drug...
Read More









